Saves the questions and what to expect into your notes, next to the visit they belong to.
Keep this study
Lead
University College London Hospitals
PRIMARY
1.1 To conduct a dose escalation safety trial of magnetic nanoparticles injected into the prostates of men prior to cystoprostatectomy. 1.2 To conduct a dose escalation safety trial of magnetic nanoparticles injected into the prostates of men prior to prostatectomy. 1.3 To evaluate ex-vivo prostates with a special marker to determine the retention and distribution of the magnetic nanoparticles in relation to the intended target area at time of injection
SECONDARY 2.1 To evaluate the anatomical distribution of magnetic nanoparticles compared with injection site in prostate assessed by both Perls' staining and postoperative imaging (MRI and CT) of the ex vivo tissue
Age
Any age
Sex
MALE
Healthy volunteers
Not accepted
You may be eligible if
1. Patients undergoing radical cystoprostatectomy for bladder cancer
2. Patients undergoing radical prostatectomy for prostate cancer
3. Patients giving informed consent
You may not be if
1. Have taken any form of hormones (except 5-alpha reductase inhibitors) within the last 6 months
2. Unable to have MRI scan or CT scan, or in whom artefact would reduce scan quality
3. Unable to have general or regional anaesthesia
4. Patients on immunosuppression or predefined immunosuppressed state
5. Patients with a coagulopathy predisposing to bleeding to clot formation
6. Patients with an inherited or acquired condition limiting metabolism of iron
